Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,279 | -5,168 | -19,482 | -9,590 | -6,463 |
| Depreciation Amortization | 67 | 33 | 605 | 564 | 370 |
| Accounts payable and accrued liabilities | -135 | -466 | 800 | 488 | 71 |
| Other Working Capital | 233 | -719 | -762 | 787 | 49 |
| Other Operating Activity | 2,061 | 2,259 | 6,095 | -122 | 157 |
| Operating Cash Flow | $-6,053 | $-4,061 | $-12,744 | $-7,873 | $-5,816 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 5,530 | 5,530 | -28 | -16 | -5 |
| Net Acquisitions | N/A | N/A | -67 | N/A | N/A |
| Other Investing Activity | 0 | 0 | 5,309 | -437 | -81 |
| Investing Cash Flow | $5,530 | $5,530 | $5,214 | $-452 | $-86 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -169 | -45 | -276 | N/A | -153 |
| Common Stock Issued | N/A | N/A | N/A | 2 | N/A |
| Other Financing Activity | 0 | 0 | 67 | -245 | 2 |
| Financing Cash Flow | $-169 | $-45 | $-209 | $-243 | $-151 |
| Beginning Cash Position | 1,249 | 1,249 | 8,988 | 8,988 | 8,988 |
| End Cash Position | 558 | 2,673 | 1,249 | 420 | 2,935 |
| Net Cash Flow | $-691 | $1,424 | $-7,739 | $-8,568 | $-6,053 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,053 | -4,061 | -12,744 | -7,873 | -5,816 |
| Capital Expenditure | -2 | -2 | -28 | -16 | -5 |
| Free Cash Flow | -6,055 | -4,063 | -12,772 | -7,888 | -5,821 |